<i id='B14C268E96'><strike id='B14C268E96'><tt id='B14C268E96'><pre id='B14C268E96'></pre></tt></strike></i>
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha
read more
1:05InthisJuly13,1985,filephoto,singerFreddieMercuryoftheBritishrockgroupQueenperformsattheLiveAidco
read more
1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha
read moreAdobeNewbreastcancerscreeningguidelinesfromtheUnitedStatesPreventiveServicesTaskForcegivetheimpressi
